跳至主要内容
临床试验/RPCEC00000083
RPCEC00000083已完成4 期

Safety assessment of Granulocyte Colony Stimulating Factor:ior LeukoCIM in oncohematologic patients.Phase IV study.

Center of Molecular Immunology(CIM)0 个研究点开始时间: 2009年7月24日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Treatment

入排标准

年龄范围
one 至 one(—)
性别
All

入选标准

  • 1.Patients who met the diagnostic criteria and/or condition of use. 2.Patients with cytologic diagnosis and/or histologically confirmed cancer of any location that are receiving QT and/or RT. 3.Patients of all ages and both sexes.

排除标准

  • 1.Patients with known hypersensitivity to products derived from cells of E.Coli or other preparations of rG-CSF. 2.Patients pregnant or breastfeeding.

研究者

发起方
Center of Molecular Immunology(CIM)

相似试验

Safety assessment of Granulocyte Colony Stimulating... | 临床试验